JWH-233
| Drug Information | |||
|---|---|---|---|
| Image | 200 | ||
| Identifiers
ATC Code DrugBank
|
Chemical Data
| ||
JWH-233 is a synthetic cannabinoid from the naphthoylindole family, which acts as a potent agonist of the cannabinoid receptors. It was developed by John W. Huffman and his team at Clemson University as part of research into the structure-activity relationships of cannabinoids.
Chemical Structure and Properties[edit | edit source]
JWH-233 is chemically classified as a naphthoylindole, which is a subclass of synthetic cannabinoids. Its chemical structure is characterized by a naphthalene group attached to a carbonyl group, which is further linked to an indole moiety. The compound has a molecular formula of C25H26O2 and a molecular weight of 374.48 g/mol.
Pharmacology[edit | edit source]
JWH-233 acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, with a higher affinity for the CB2 receptor. This receptor selectivity is of interest for potential therapeutic applications, as CB2 receptor activation is associated with anti-inflammatory and immunomodulatory effects, while CB1 receptor activation is primarily responsible for the psychoactive effects of cannabinoids.
Potential Applications[edit | edit source]
Research into JWH-233 and similar compounds is ongoing, with potential applications in the treatment of pain, inflammation, and other conditions where modulation of the endocannabinoid system may be beneficial. However, the use of JWH-233 in clinical settings is limited due to its legal status and potential for abuse.
Legal Status[edit | edit source]
The legal status of JWH-233 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. Researchers must obtain special licenses to study this compound in countries where it is regulated.
Safety and Toxicology[edit | edit source]
As with many synthetic cannabinoids, the safety profile of JWH-233 is not well-established. There is limited data on its toxicity, but it is known that synthetic cannabinoids can cause adverse effects such as anxiety, paranoia, tachycardia, and in severe cases, psychosis or seizures.
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
